Spexis AG

POLN

CH0106213793

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:10 2024-05-10 am EDT			5-day change	1st Jan Change
0.0634 ^CHF	+0.63%		+16.97%	+54.63%

May. 01	SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication	MT
Apr. 17	Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	MT

Polyphor Appoints Debra Barker as Chief Medical and Development Officer, Effective May 01, 2017

March 06, 2017 at 06:00 am EST

Polyphor announced the appointment of Dr. Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO). Dr. Barker joins Polyphor effective May 01, 2017. Her significant experience in infectious and respiratory diseases and immunology and her leadership make her the perfect fit and will be instrumental to Polyphor's Pharma business.

Latest news about Spexis AG

SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication	May. 01	MT
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	Apr. 17	MT
Swiss Court OKs Moratorium Extension for Spexis	Apr. 17	MT
Basilea Pharmaceutica Receives Grant for Antibiotics Program	Apr. 09	MT
Ascom Hires New CFO	Mar. 21	MT
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea	Feb. 08	MT
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis	Jan. 15	MT
Spexis Secures Debt-restructuring Moratorium From Swiss Court	Dec. 05	MT
Spexis Seeks Loan Restructuring to Support Cystic Fibrosis Drug Study	Nov. 29	MT
Spexis to File for Debt-restructuring Moratorium in Switzerland; Stock Sinks	Nov. 08	MT
Spexis CFO to Step Down, Interim CFO Named	Nov. 01	MT
Spexis AG Announces Executive Changes, Effective December 1, 2023	Nov. 01	CI
Muriel Fleming Joins Spexis AG as Executive Committee, Effective December 1, 2023	Nov. 01	CI
Transcript : Polyphor AG - Special Call	23-10-09
Spexis Posts Lower H1 Attributable Loss	23-09-29	MT
Spexis AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Spexis AG Announces Appointment of Gonçalo Bernardes as Acting Head of Chemical Biology	23-09-28	CI
Spexis Secures Investment Pledge from SPRIM Global, Other Investors for ColiFin Trial	23-08-15	MT
Spexis AG announced that it has received $2.5 million in funding from SPRIM Ventures and other investors	23-08-13	CI
Spexis Enlists Financial Adviser to Evaluate Strategic Alternatives, Fundraising Opportunities	23-06-30	MT
Spexis AG Announces the Publication of Preclinical Results from its Novel Class of Macrocyclic, Peptidomimetic Antibiotics Developed in Collaboration with the University of Zurich	23-06-07	CI
Spexis AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-30	CI
Spexis Posts Higher FY22 Attributable Net Loss; Operating Loss Widens	23-05-30	MT
Destiny Pharma picks interim CEO as Clark makes quick exit	23-05-25	AN
Spexis Receives Extension for Publication of 2022 Annual Report	23-04-28	MT

Chart Spexis AG

Duration

Period

More charts

Company Profile

Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.

Sector

Pharmaceuticals

Calendar

2024-09-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SPEXIS AG	+54.63%	4.73M
CSL LIMITED	-2.61%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals

Spexis AG

Equities

POLN

CH0106213793

Pharmaceuticals

Polyphor Appoints Debra Barker as Chief Medical and Development Officer, Effective May 01, 2017

Latest news about Spexis AG

Chart Spexis AG

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Biopharmaceuticals